Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Alector, Inc. has received an average rating of "Hold" from seven research firms, with two analysts recommending sell, one hold, and four buy ratings.
• Insider trading showed Director Paula Hammond sold 14,000 shares, representing a 15.75% decrease in her position, while corporate insiders collectively own 9.70% of the company's stock.
• For the last quarter, Alector reported earnings of ($0.30) EPS, exceeding estimates, with revenue of $7.87 million compared to an expectation of $2.76 million.

Alector, Inc. (NASDAQ:ALEC - Get Free Report) has been assigned an average recommendation of "Hold" from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $4.1667.

Several research analysts have recently commented on ALEC shares. Wall Street Zen raised Alector from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Mizuho raised shares of Alector from a "neutral" rating to an "outperform" rating and lifted their price target for the stock from $2.50 to $3.50 in a report on Monday, July 28th.

Alector Price Performance

ALEC stock traded up $0.15 during trading hours on Monday, hitting $3.18. 1,112,584 shares of the stock traded hands, compared to its average volume of 1,227,476. Alector has a one year low of $0.87 and a one year high of $6.14. The company has a current ratio of 3.78, a quick ratio of 3.78 and a debt-to-equity ratio of 0.13. The company has a market cap of $321.85 million, a P/E ratio of -2.74 and a beta of 0.99. The stock has a 50-day simple moving average of $2.22 and a 200 day simple moving average of $1.62.

Alector (NASDAQ:ALEC - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $7.87 million during the quarter, compared to analyst estimates of $2.76 million. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. Alector has set its FY 2025 guidance at EPS. Equities analysts forecast that Alector will post -1.88 earnings per share for the current year.

Insider Activity at Alector

In other Alector news, Director Paula Hammond sold 14,000 shares of the company's stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the transaction, the director directly owned 74,909 shares in the company, valued at approximately $176,785.24. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 9.70% of the company's stock.

Institutional Investors Weigh In On Alector

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC grew its position in Alector by 39.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company's stock valued at $1,768,000 after buying an additional 410,205 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Alector by 5.6% during the 4th quarter. Northern Trust Corp now owns 759,874 shares of the company's stock worth $1,436,000 after buying an additional 40,291 shares during the period. BNP Paribas Financial Markets increased its position in Alector by 723.0% during the fourth quarter. BNP Paribas Financial Markets now owns 165,589 shares of the company's stock worth $313,000 after acquiring an additional 145,469 shares during the period. Ieq Capital LLC acquired a new position in shares of Alector in the first quarter valued at $99,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Alector by 12.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,570 shares of the company's stock valued at $303,000 after acquiring an additional 17,509 shares during the period. Institutional investors own 85.83% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.